If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
239
results.
Updated on
15/07/2026 [07:04:00]
Results 125 to 150 of 239
Absstract of: WO2026107790A1
Disclosed in the present invention is a blood glucose management system for establishing a wireless communication connection on the basis of signal strength. A signal strength threshold is preset in the blood glucose management system. During a period when a monitoring module and/or an infusion module is powered on and sends a broadcast signal, a program module searches for a nearby broadcast signal and identifies the signal strength of the broadcast signal. When the signal strength of the broadcast signal is not less than the preset signal strength threshold, the program module can establish a wireless communication connection with the monitoring module and/or the infusion module that sends the broadcast signal, without the need to input a device identifier of the monitoring module and/or the infusion module. Moreover, since the broadcast signal identified by the program module is sufficiently strong, it means that the program module is in proximity to the monitoring module and/or the infusion module that sends the broadcast signal, thereby ensuring the reliability of the program module establishing a wireless communication connection with a patient's own monitoring module and/or infusion module.
Absstract of: US20260144928A1
0000 Provided herein are systems and methods for delivering medication, such as insulin, that are user-friendly, environmentally-friendly, lower cost, discreet, less prone to errors, and/or that deliver precise, repeatable doses of medication, as well as accessories for applying and managing the same. In embodiments, the system includes a wearable insulin pump having a patch-style form factor for adhesion to a user's body surface.
Absstract of: SK3002025U1
System for determining biological age and life expectancy trend based on continuously measured glycemia processes CGM data using the internal AGE Index / BVI algorithm, which determines biological age and the trend of its changes. Increased glycemia is associated with accelerated biological aging. The system provides indicative information about biological age, its trend and the risk of premature mortality.
Absstract of: EP4748307A1
The present technology relates to a measurement apparatus capable of improving measurement accuracy.The measurement apparatus includes: a circuit portion that is arranged on one surface of a sensor substrate and measures an S parameter; and a sensor electrode that is arranged on the other surface of the sensor substrate and irradiates a measurement target with a signal for measuring the S parameter output from the circuit portion, in which a distance between the circuit portion and the sensor electrode is equal to or less than a predetermined distance in plan view, and a terminal that outputs the signal of the circuit portion is directly connected to the sensor substrate. The present technology can be applied to a glucose sensing system.
Absstract of: EP4748379A1
0001 A use of uridine diphosphate glucose (UDPG) in treatment of abnormal liver glucolipid metabolism. Specifically, a use of UDPG or a pharmaceutical composition comprising same in the preparation of a drug for preventing and/or treating abnormal liver glucolipid metabolism, wherein the abnormal liver glucolipid metabolism is preferably nonalcoholic fatty liver disease, dyslipidemia and related cardiovascular diseases. Treatment using UDPG can reduce lipid synthesis and lipid synthesis related gene expression in the liver.
Absstract of: EP4749952A2
0001 The present invention relates generally to systems and methods for processing, transmitting, and displaying data received from continuous analyte sensor 10, such as a glucose sensor. In some embodiments, the continuous analyte sensor system 8 comprises a sensor electronics module 12 that includes power saving features. One feature includes a low power measurement circuit that can be switched between a measurement mode and a low power mode, in which charging circuitry continues to apply power to electrodes of a sensor during the low power mode. In addition, the sensor electronics module can be switched between in a low power storage mode higher power operational mode via a switch. The switch can include a reed switch or optical switch, for example. A validation routine can also be implemented to ensure an interrupt signal sent from the switch is valid. The continuous analyte sensor 10 can be physically connected to a sensor electronics module 12, which is in direct wireless communication with a plurality of different display devices 14, 16, 18, and/or 20.
Absstract of: EP4749425A2
0001 A system, a method, and a computer program product for providing wearable continuous blood glucose monitoring. In some embodiments, there is provided a method that includes receiving, at a smartwatch, an alert representative of a glucose state of a host-patient coupled to a glucose sensor; detecting, at the smartwatch, a predetermined action indicative of a request to generate a glance view providing an indication of the glucose state of the host-patient; and presenting, at the smartwatch and in response to the detecting, the glance view providing the indication of the glucose state of the host-patient.
Absstract of: EP4748312A1
This application discloses a measurement method, a system, and a related apparatus. The method is applied to a first electronic device, the first electronic device includes a first electrode group and a second electrode group, and a distance between the first electrode group and the second electrode group is greater than a first distance. When the first electrode group and the second electrode group are implanted into a subcutaneous tissue, the method includes: determining a first physiological parameter by using the first electrode group; and determining an electrocardiography signal by using the first electrode group and the second electrode group. In this way, the first electronic device may obtain an electrocardiography signal of a user anytime and anywhere, and may further measure one or more other physiological parameters (for example, blood glucose, blood ketone, blood lactic acid, and uric acid) of the user at the same time, to improve health monitoring efficiency.
Absstract of: EP4748310A2
The present invention relates to a body attachment unit for continuous blood glucose monitoring, in which a body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work and allowing attachment of the body attachment unit to a body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without additional work of connecting a separate transmitter, and allowing easier maintenance. In addition, activation occurs by a user's operation after the body attachment unit is attached to the body, such that an activation start time can be adjusted to a time appropriate to the user's needs, and activation can occur in a stabilized state, and thereby allowing more accurate blood glucose monitoring.
Absstract of: EP4748398A2
0001 Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein.
Absstract of: US20260137312A1
A device for delivery of an insulin or insulin analog formulation and measurement of subcutaneous glucose concentration may comprise a hollow tube, and an amperometric glucose sensor located proximal to a distal end of the hollow tube. The amperometric glucose sensor may comprise a redox mediator and an enzyme comprising glucose oxidase or glucose dehydrogenase. An applied bias potential may allow an electrode layer of the amperometric glucose sensor to undergo substantially no electropolymerization of an excipient of the insulin or insulin analog formulation during continuous operation of amperometric glucose sensor. A sensitivity of the amperometric glucose sensor to the subcutaneous glucose concentration may be maintained in presence of the insulin or insulin analog formulation.
Absstract of: WO2026106928A1
Ambulatory infusion pump systems can integrate a CGM sensor with an ambulatory infusion pump via a pump holder or tray that releasably holds the pump and is configured to be worn by a user. By combining the CGM and insulin pump into one integrated system, a more aesthetically pleasing, convenient and reliable system is provided. Diabetes management is simplified by consolidating two essential devices into one.
Absstract of: US20260137310A1
0000 Disclosed are examples that include receiving information related to ingestion of a meal. The information may include a coarse indication of a size of the meal, a relative time of ingestion of the meal, and a general composition indication of the meal. A blood glucose measurement value received within a predetermined time range of a relative time of ingestion of the meal may be identified. Settings for a delay and an extend parameter and a delivery constraint may be determined. A meal model may be modified using the determined settings for the delay parameter, the extend parameter, and the delivery constraint. The modified meal model may be used to determine a dose of insulin to be delivered in response to the received information. An instruction indicates a determined dose of insulin to be delivered may be output for delivery to a drug delivery device.
Absstract of: US20260137313A1
0000 A compensation method for a continuous glucose monitor includes: acquiring a glucose value of a user continuously; determining a user type and a glucose trend type according to the glucose value, where the user type includes at least a first user type and a second user type; determining, based on the glucose value, whether a compensation start condition is satisfied; starting a compensation algorithm if the compensation start condition is satisfied; determining a compensation formula based on the glucose value and the glucose trend type; and obtaining, based on the glucose value and the compensation formula, a compensated glucose value until a compensation stop condition is satisfied.
Absstract of: US2020178899A1
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Absstract of: WO2026107395A1
The disclosure relates to a cryopreservation medium comprising a diol, sugar, or both a diol and sugar. The disclosure also provides a use of the cryopreservation medium to cryopreserve a cell, a method of preparing a cell for preservation, and a method of cryopreserving a cell.
Absstract of: WO2026106887A1
Methods and systems are configured for maintaining closed loop therapy in circumstances where a phone or other user device providing therapy commands to the pump according to a closed loop therapy algorithm becomes disconnected from the pump. A fallback or backup closed loop algorithm can be stored on the pump that may be a simplified version of the closed loop algorithm operated on the phone having lower memory and computational requirements such that it can be operated on the pump. The fallback algorithm may also require less battery power to be operated. If the pump detects that the connection with the phone has been lost, the pump can establish communications with the CGM to receive the glucose levels (if not already connected). The pump can then activate the fallback close loop algorithm stored on the pump and make therapy determinations based on the CGM data according to the fallback closed loop algorithm.
Absstract of: AU2023200010A1
The present disclosure relates to a continuous glucose monitoring device, in which a body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work for a user in attaching the body attachment unit to a body, and allowing attachment of the body attachment unit to the body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without additional work of connecting a separate transmitter, and allowing easier maintenance. In addition, the continuous glucose monitoring device is activated by a user's operation after the body attachment unit is attached to the body, such that an activation start time can be adjusted to a time appropriate to the user's needs, and the continuous glucose monitoring device can be activated in a stabilized state, and thereby can monitor blood glucose more accurately.
Absstract of: US20260137353A1
Methods of predicting insulin resistance in a subject are provided. The methods include measuring interstitial fluid glucose in the subject over a period of time to obtain a plurality of glucose values (G(tn)); fitting the measured plurality of glucose values (G(tn)) to a glucose-insulin response model to calculate a plurality of subject-specific parameters, the glucose-insulin response model comprising a modified Lotka-Volterra system of equations for the glucose-insulin response pair (G(t), I(t)); and comparing at least one of the calculated subject-specific parameters to a set threshold value to predict insulin resistance in the subject. Systems for predicting insulin resistance in a subject are also provided. The systems include a continuous glucose monitoring (CGM) sensor and a computation device.
Absstract of: WO2026103909A1
A method for preparing an MOF-based glucose detection system, wherein a Zeolitic Imidazolate Framework (ZIF) is used as a metal-organic framework, and glucose oxidase (GOx) is loaded in the zeolitic imidazolate framework. The preparation method comprises the following steps: S1: adding water to a reaction flask in advance, and then sequentially adding a metal ion, an enzyme and an organic ligand in a molar ratio of 100-1500:1-10:1-150, and 0.1-0.5% (by weight) of ammonia water to the reaction flask, S2: mixing and reacting same at room temperature for more than 6 hours, and S3: after centrifugation by means of a centrifuge, removing the supernatant to obtain a solid precipitate of the Gox-MOF material loaded with glucose oxidase. A sensor for detecting trace glucose concentration in saliva, and an oral glucose meter comprising the sensor.
Absstract of: US12629065B1
0000 A continuous glucose monitor (CGM) sensor includes a glucose oxidation electrode and a counter electrode, and does not include a glucose-specific enzyme. The glucose oxidation electrode includes a nanoporous layer comprising metal nanoparticles. The CGM sensor generates an electrical signal indicative glucose oxidation in a liquid containing glucose, which has a correlation with an effective surface area of the metal nanoparticles in the nanoporous layer. When the CGM sensor is implanted in a subject's body, an AC voltage is applied between the glucose oxidation electrode and the counter electrode, and impedance is obtained. A glucose level for the subject is determined using the impedance without use of information or data related to glucose sensitivity of a sensor or sensors over use or time.
Absstract of: US12629058B1
An integrated glucose monitoring system may include a glucometer and an electronic temperature sensor. The glucometer may be configured to attach to a mobile device. The glucometer may include a test strip aperture, measurement electronics, an electronics port, and/or a cooling vent configured to vent air across the measurement electronics. The temperature sensor may be physically coupled to the glucometer. The temperature sensor may be exposed from the glucometer to an ambient environment approximate the glucometer. The temperature sensor may be electronically coupled to the measurement electronics. The measurement electronics may be configured to adjust a blood glucose reading based on an ambient temperature reading taken by the electronic temperature sensor approximately concurrently with the blood glucose reading.
Absstract of: WO2026100393A1
In the present invention, a program causes a computer to execute processing for: acquiring time series data indicating the glucose level and the lactate level of a patient in a time series; estimating the blood glucose level of the patient after a prescribed period of time on the basis of the time series data of the glucose level and the lactate level; and determining a dosage of insulin to the patient on the basis of the estimated blood glucose level. Preferably, the program estimates the blood glucose level after a prescribed period of time by inputting the acquired time-series data of the glucose level and the lactate value into a model trained so as to estimate the blood glucose level after the prescribed period of time when the time-series data of the glucose level and the lactate level is input.
Absstract of: WO2026102201A1
The present application provides modified Chymotrypsin-like ELAstase 2A (CELA2A) proteins such as catalytically inactivate and protease resistant CELA2A proteins. Also provided herein are the uses of the CELA2A proteins for preserving pancreatic islet size, number as well as enhancing insulin secreting and insulin signaling and for the treatment of diabetes, pancreatitis and other related diseases.
Nº publicación: WO2026102433A1 15/05/2026
Applicant:
KYOCERA AVX COMPONENTS SAN DIEGO INC [US]
KYOCERA AVX COMPONENTS (SAN DIEGO), INC.
Absstract of: WO2026102433A1
A glucose monitoring device is provided. The glucose monitoring device includes a housing having a first portion and a second portion, the second portion operable to be placed adjacent to a human body during operation of the glucose monitoring device. The glucose monitoring device further includes a circuit board positioned between the first portion and the second portion of the housing, the circuit board having a trace antenna. The glucose monitoring device further includes a conductive structure spaced apart from the circuit board.
BOPI
Electronic site
